Treatment of malaria in the United States: A systematic review

JAMA

Volumn 297, Issue 20, 2007, Pages 2264-2277

  Griffith, Kevin S ^a   Lewis, Linda S ^b   Mali, Sonja ^a   Parise, Monica E ^a,c  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^b UNIVERSITY OF CALIFORNIA COOPERATIVE EXTENSION   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; ANTIMALARIAL AGENT; ARTEMISIN; ARTESUNATE; ATOVAQUONE PLUS PROGUANIL; BARBITURIC ACID DERIVATIVE; CARBAMAZEPINE; CHLOROQUINE; CHLOROQUINE PLUS PROGUANIL; CLINDAMYCIN; DEXAMETHASONE; DICHLOROACETIC ACID; DOXYCYCLINE; FANSIDAR; HALOFANTRINE; HEPARIN; HYDROXYCHLOROQUINE; IRON CHELATING AGENT; MEFLOQUINE; PARACETAMOL; PENTOXIFYLLINE; PHENOBARBITAL; PHENYTOIN; PRIMAQUINE; QUINIDINE; QUINIDINE GLUCONATE; QUININE; QUININE SULFATE; TETRACYCLINE;

ABDOMINAL PAIN; AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC THERAPY; ATRIOVENTRICULAR BLOCK; ATRIOVENTRICULAR JUNCTION ARRHYTHMIA; BRADYCARDIA; BRAIN MALARIA; BRAIN PSEUDOTUMOR; CHEMOPROPHYLAXIS; CLINICAL FEATURE; CONTINUOUS INFUSION; DAIRY PRODUCT; DIAGNOSTIC ACCURACY; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; DIZZINESS; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG PROTEIN BINDING; DRUG SAFETY; ECG ABNORMALITY; ESOPHAGITIS; EXCHANGE BLOOD TRANSFUSION; FATIGUE; FEVER; FIBRINOGEN BLOOD LEVEL; FOOD; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; HEARING IMPAIRMENT; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HEMOLYSIS; HOSPITAL PHARMACY; HUMAN; HYPERPYREXIA; HYPOGLYCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOTENSION; INTENSIVE CARE; INTRAVASCULAR HEMOLYSIS; LABORATORY TEST; LIVER TOXICITY; LOADING DRUG DOSE; MALARIA; MALARIA CONTROL; MALARIA FALCIPARUM; MEDLINE; MENTAL DISEASE; METABOLIC ACIDOSIS; METHEMOGLOBINEMIA; MILK; MYALGIA; NAUSEA; NAUSEA AND VOMITING; NEPHROTOXICITY; ODYNOPHAGIA; PANCREATITIS; PARASITEMIA; PATIENT MONITORING; PHOTOSENSITIVITY; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PREGNANT WOMAN; PRIORITY JOURNAL; PRURITUS; QRS COMPLEX; QT PROLONGATION; REVIEW; RISK BENEFIT ANALYSIS; SEIZURE; SIDE EFFECT; SINUS ARRHYTHMIA; SINUS BRADYCARDIA; SLEEP DISORDER; SOMNOLENCE; SYSTEMATIC REVIEW; T WAVE; TACHYCARDIA; THROMBOCYTOPENIA; TINNITUS; TRAVEL; TREATMENT DURATION; TREATMENT OUTCOME; UNITED STATES; URTICARIA; VISUAL DISORDER; ALGORITHM; ANIMAL; GROWTH, DEVELOPMENT AND AGING; ISOLATION AND PURIFICATION; LIFE CYCLE; PLASMODIUM;

ALGORITHMS; ANIMALS; ANTIMALARIALS; HUMANS; LIFE CYCLE STAGES; MALARIA; PLASMODIUM; UNITED STATES;

EID: 34249695002     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.297.20.2264     Document Type: Review

References (209)

1. Skarbinski J, James EM, Causer LM, et al. Malaria surveillance-United States, 2004. MMWR Surveill Summ. 2006;55:23-37.
2. Newman RD, Parise ME, Barber AM, Steketee RW. Malaria-related deaths among U.S. travelers, 1963-2001. Ann Intern Med. 2004;141:547-555.
3. Mendis K, Sina BJ, Marchesini P, Carter R. The neglected burden of Plasmodium vivax malaria. Am J Trop Med Hyg. 2001;64(1-2 suppl):97-106.
4. Health Information for International Travel 2005-2006. Atlanta, Ga: Elsevier Inc; 2005.
5. Baird JK, Hoffman SL. Primaquine therapy for malaria. Clin Infect Dis. 2004;39:1336-1345.
6. Marlar T, Myat Phone K, Aye Yu S, Khaing Khaing G, Ma S, Myint O. Development of resistance to chloroquine by Plasmodium vivax in Myanmar. Trans R Soc Trop Med Hyg. 1995;89:307-308.
7. Jamaiah I, Anuar AK, Najib NA, Zurainee MN. Imported malaria: a retrospective study in University Hospital, Kuala Lumpur, a ten-year experience. Med J Malaysia. 1998;53:6-9.
8. Phan GT, De Vries PJ, Tran BQ, et al. Artemisinin or chloroquine for blood stage Plasmodium vivax malaria in Vietnam. Trop Med Int Health. 2002;7:858-864.
9. Singh RK. Emergence of chloroquine-resistant vivax malaria in south Bihar (India). Trans R Soc Trop Med Hyg. 2000;94:327.
10. Kurcer MA, Simsek Z, Kurcer Z. The decreasing efficacy of chloroquine in the treatment of Plasmodium vivax malaria, in Sanliurfa, south-eastern Turkey. Ann Trop Med Parasitol. 2006;100:109-113.
11. Kurcer MA, Simsek Z, Zeyrek FY, et al. Efficacy of chloroquine in the treatment of Plasmodium vivax malaria in Turkey. Ann Trop Med Parasitol. 2004;98:447-451.
12. Sinden REG. The malaria parasites. In: Warrell DA, Gilles HM, eds. Essential Malariology. 4th ed. London, England: Arnold; 2002:26, 30.
13. Molineaux L. The epidemiology of human malaria as an explanation of its distribution, including some implications for its control. In: Wernsdorfer WH, ed. Malaria, Principles and Practice of Malariology, Volume 2. Edinburgh, Scotland: Churchill Livingstone; 1988:927.
14. Garnham P. Malaria parasites of man: life-cycles and morphology. In: Wernsdorfer WH, McGregor I, eds. Malaria: Principles and Practice of Malariology, Volume 1. London, England: Churchill Livingstone; 1988:69.
15. Dorsey G, Gandhi M, Oyugi JH, Rosenthal PJ. Difficulties in the prevention, diagnosis, and treatment of imported malaria. Arch Intern Med. 2000;160:2505-2510.
16. Moore TA, Tomayko JF Jr, Wierman AM, Rensimer ER, White AC Jr. Imported malaria in the 1990s: a report of 59 cases from Houston, Tex. Arch Fam Med. 1994;3:130-136.
17. Singh K, Wester WC, Trenholme GM. Problems in the therapy for imported malaria in the United States. Arch Intern Med. 2003;163:2027-2030.
18. Svenson JE, MacLean JD, Gyorkos TW, Keystone J. Imported malaria: clinical presentation and examination of symptomatic travelers. Arch Intern Med. 1995;155:861-868.
19. Lynk A, Gold R. Review of 40 children with imported malaria. Pediatr Infect Dis J. 1989;8:745-750.
20. McCaslin RI, Pikis A, Rodriguez WJ. Pediatric Plasmodium falciparium malaria: a ten-year experience from Washington, DC. Pediatr Infect Dis J. 1994;13:709-715.
21. World Health Organization. WHO Guidelines for the Treatment of Malaria. Geneva, Switzerland: WHO Press; 2000.
22. World Health Organization. WHO Guidelines for the Treatment of Malaria. Geneva, Switzerland:WHO Press; 2006.
23. Beg MA, Khan R, Baig SM, Gulzar Z, Hussain R, Smego RA Jr. Cerebral involvement in benign tertian malaria. Am J Trop Med Hyg. 2002;67:230-232.
24. Curlin ME, Barat LM, Walsh DK, Granger DL. Noncardiogenic pulmonary edema during vivax malaria. Clin Infect Dis. 1999;28:1166-1167.
25. Islam N, Qamruddin K. Unusual complications in benign tertian malaria. Trop Geogr Med. 1995;47:141-143.
26. Kochar DK, Saxena V, Singh N, Kochar SK, Kumar SV, Das A. Plasmodium vivax malaria. Emerg Infect Dis. 2005;11:132-134.
27. Muhlberger N, Jelinek T, Gascon J, et al. Epidemiology and clinical features of vivax malaria imported to Europe: sentinel surveillance data from TropNetEurop. Malar J. 2004;3:5.
28. Sachdev HS, Mohan M. Vivax cerebral malaria. J Trop Pediatr. 1985;31:213-215.
29. Tanios MA, Kogelman L, McGovern B, Hassoun PM. Acute respiratory distress syndrome complicating Plasmodium vivax malaria. Crit Care Med. 2001;29:665-667.
30. Zingman BS, Viner BL. Splenic complications in malaria: case report and review. Clin Infect Dis. 1993; 16:223-232.
31. Moody A. Rapid diagnostic tests for malaria parasites. Clin Microbiol Rev. 2002;15:66-78.
32. Greenwood BM, Bradley AK, Greenwood AM, et al. Mortality and morbidity from malaria among children in a rural area of The Gambia, West Africa. Trans R Soc Trop Med Hyg. 1987;81:478-486.
33. Kain KC, Gadd E, Gushulak B, McCarthy A, MacPherson D. Errors in treatment recommendations for severe malaria. Committee to Advise on Tropical Medicine and Travel (CATMAT). Lancet. 1996;348:621-622.
34. D'Acremont V, Landry P, Mueller I, Pecoud A, Genton B. Clinical and laboratory predictors of imported malaria in an outpatient setting: an aid to medical decision making in returning travelers with fever. Am J Trop Med Hyg. 2002;66:481-486.
35. Caillon E, Schmitt L, Moron P. Acute depressive symptoms after mefloquine treatment. Am J Psychiatry. 1992;149:712.
36. Ekue JM, Simooya OO, Sheth UK, Wernsdorfer WH, Njelesani EK. A double-blind clinical trial of a combination of mefloquine, sulfadoxine and pyrimethamine in symptomatic falciparum malaria. Bull World Health Organ. 1985;63:339-343.
37. Harinasuta T, Bunnag D, Wernsdorfer WH. A phase II clinical trial of mefloquine in patients with chloroquine-resistant falciparum malaria in Thailand. Bull World Health Organ. 1983;61:299-305.
38. Hennequin C, Bouree P, Bazin N, Bisaro F, Feline A. Severe psychiatric side effects observed during prophylaxis and treatment with mefloquine. Arch Intern Med. 1994;154:2360-2362.
39. Luxemburger C, Nosten F, ter Kuiile F, Frejacques L, Chongsuphajaisiddhi T, White NJ. Mefloquine for multidrug-resistant malaria. Lancet. 1991;338:1268.
40. Marsepoil T, Petithory J, Faucher JM, Ho P, Viriot E, Benaiche F. Encephalopathy and memory disorders during treatments with mefloquine [article in French]. Rev Med Interne. 1993;14:788-791.
41. Patchen LC, Campbell CC, Williams SB. Neurologic reactions after a therapeutic dose of mefloquine. N Engl J Med. 1989;321:1415-1416.
42. Phillips-Howard PA, ter Kuile FO. CNS adverse events associated with antimalarial agents: fact or fiction? Drug Saf. 1995;12:370-383.
43. Price R, van Vugt M, Phaipun L, et al. Adverse effects in patients with acute falciparum malaria treated with artemisinin derivatives. Am J Trop Med Hyg. 1999;60:547-555.
44. Rendi-Wagner P, Noedl H, Wernsdorfer WH, Wiedermann G, Mikolasek A, Kollaritsch H. Unexpected frequency, duration and spectrum of adverse events after therapeutic dose of mefloquine in healthy adults. Acta Trop. 2002;81:167-173.
45. Rouveix B, Bricaire F, Michon C, et al. Mefloquine and an acute brain syndrome. Ann Intern Med. 1989;110:577-578.
46. Sowunmi A. Acute psychosis after mefloquine: a case report. East Afr Med J. 1994;71:818-819.
47. Sowunmi A, Adio RA, Oduola AM, Ogundahunsi OA, Salako LA. Acute psychosis after mefloquine: report of six cases. Trop Geogr Med. 1995;47:179-180.
48. Sowunmi A, Salako LA, Oduola AM, Walker O, Akindele JA, Ogundahunsi OA. Neuropsychiatric side effects of mefloquine in Africans. Trans R Soc Trop Med Hyg. 1993;87:462-463.
49. Speich R, Haller A. Central anticholinergic syndrome with the antimalarial drug mefloquine. N Engl J Med. 1994;331:57-58.
50. Weinke T, Trautmann M, Held T, et al. Neuropsychiatric side effects after the use of mefloquine. Am J Trop Med Hyg. 1991;45:86-91.
51. Stuiver PC, Ligthelm RJ, Goud TJ. Acute psychosis after mefloquine. Lancet. 1989;2:282.
52. de Alencar FE, Cerutti C Jr, Durlacher RR, et al. Atovaquone and proguanil for the treatment of malaria in Brazil. J Infect Dis. 1997;175:1544-1547.
53. Barata LC, Boulos M, Dutra AP. Use of tetracycline and quinine combination in the treatment of Plasmodium falciparum malaria [article in Portuguese]. Rev Soc Bras Med Trop. 1986;19:135-137.
54. Bunnag D, Karbwang J, Na-Bangchang K, Thanavibul A, Chittamas S, Harinasuta T. Quinine-tetracycline for multidrug resistant falciparum malaria. Southeast Asian J Trop Med Public Health. 1996;27:15-18.
55. Clyde DF, Gilman RH, McCarthy VC. Antimalarial effects of clindamycin in man. Am J Trop Med Hyg. 1975;24:369-370.
56. Colwell EJ, Hickman RL, Kosakal S. Quininetetracycline and quinine-bactrim treatment of acute falciparum malaria in Thailand. Ann Trop Med Parasitol. 1973;67:125-132.
57. Colwell EJ, Hickman RL, Kosakal S. Tetracycline treatment of chloroquine-resistant falciparum malaria in Thailand. JAMA. 1972;220:684-686.
58. Hall AP, Doberstyn EB, Nanokorn A, Sonkom P. Falciparum malaria semi-resistant to clindamycin. Br Med J. 1975;2:12-14.
59. Karbwang J, Molunto P, Bunnag D, Harinasuta T. Plasma quinine levels in patients with falciparum malaria when given alone or in combination with tetracycline with or without primaquine. Southeast Asian J Trop Med Public Health. 1991;22:72-76.
60. Karbwang J, Na-Bangchang K, Thanavibul A, Bunnag D, Chongsuphajaisiddhi T, Harinasuta T. Comparison of oral artesunate and quinine plus tetracycline in acute uncomplicated falciparum malaria. Bull World Health Organ. 1994;72:233-238.
61. Kremsner PG, Winkler S, Brandts C, Neifer S, Bienzle U, Graninger W. Clindamycin in combination with chloroquine or quinine is an effective therapy for uncomplicated Plasmodium falciparum malaria in children from Gabon. J Infect Dis. 1994;169:467-470.
62. Kremsner PG, Zotter GM, Feldmeier H, Graninger W, Rocha RM, Wiedermann G. A comparative trial of three regimens for treating uncomplicated falciparum malaria in Acre, Brazil. J Infect Dis. 1988;158:1368-1371.
63. Looareesuwan S, Vanijanonta S, Viravan C, et al. Randomised trial of mefloquine-tetracycline and quinine-tetracycline for acute uncomplicated falciparum malaria. Acta Trop. 1994;57:47-53.
64. Looareesuwan S, Wilairatana P, Vanijanonta S, Kyle D, Webster K. Efficacy of quinine-tetracycline for acute uncomplicated falciparum malaria in Thailand. Lancet. 1992;339:369.
65. McGready R, Cho T, Samuel , et al. Randomized comparison of quinine-clindamycin versus artesunate in the treatment of falciparum malaria in pregnancy. Trans R Soc Trop Med Hyg. 2001;95:651-656.
66. Metzger W, Mordmuller B, Graninger W, Bienzle U, Kremsner PG. High efficacy of short-term quinine-antibiotic combinations for treating adult malaria patients in an area in which malaria is hyperendemic. Antimicrob Agents Chemother. 1995;39:245-246.
67. Miller LH, Glew RH, Wyler DJ, et al. Evaluation of clindamycin in combination with quinine against multidrug-resistant strains of Plasmodium falciparum. Am J Trop Med Hyg. 1974;23:565-569.
68. Parola P, Ranque S, Badiaga S, et al. Controlled trial of 3-day quinine-clindamycin treatment versus 7-day quinine treatment for adult travelers with uncomplicated falciparum malaria imported from the tropics. Antimicrob Agents Chemother. 2001;45:932-935.
69. Pukrittayakamee S, Chantra A, Vanijanonta S, Clemens R, Looareesuwan S, White NJ. Therapeutic responses to quinine and clindamycin in multidrug-resistant falciparum malaria. Antimicrob Agents Chemother. 2000;44:2395-2398.
70. Pukrittayakamee S, Chotivanich K, Chantra A, Clemens R, Looareesuwan S, White NJ. Activities of artesunate and primaquine against asexual- and sexual-stage parasites in falciparum malaria. Antimicrob Agents Chemother. 2004;48:1329-1334.
71. Reacher M, Campbell CC, Freeman J, Doberstyn EB, Brandling-Bennett AD. Drug therapy for Plasmodium falciparum malaria resistant to pyrimethamine- sulfadoxine (Fansidar): a study of alternate regimens in Eastern Thailand, 1980. Lancet. 1981;2:1066-1069.
72. Vaillant M, Millet P, Luty A, et al. Therapeutic efficacy of clindamycin in combination with quinine for treating uncomplicated malaria in a village dispensary in Gabon. Trop Med Int Health. 1997;2:917-919.
73. Vanijanonta S, Chantra A, Phophak N, Chindanond D, Clemens R, Pukrittayakamee S. Therapeutic effects of chloroquine in combination with quinine in uncomplicated falciparum malaria. Ann Trop Med Parasitol. 1996;90:269-275.
74. Andersen SL, Oloo AJ, Gordon DM, et al. Successful double-blinded, randomized, placebo-controlled field trial of azithromycin and doxycycline as prophylaxis for malaria in western Kenya. Clin Infect Dis. 1998;26:146-150.
75. Baudon D, Martet G, Pascal B, Bernard J, Keundjian A, Laroche R. Efficacy of daily antimalarial chemoprophylaxis in tropical Africa using either doxycycline or chloroquine-proguanil: a study conducted in 1996 in the French Army. Trans R Soc Trop Med Hyg. 1999;93:302-303.
76. Karwacki JJ, Shanks GD, Kummalue T, Watanasook C. Primaquine induced hemolysis in a Thai soldier. Southeast Asian J Trop Med Public Health. 1989;20:555-556.
77. Ohrt C, Richie TL, Widjaja H, et al. Mefloquine compared with doxycycline for the prophylaxis of malaria in Indonesian soldiers: a randomized, doubleblind, placebo-controlled trial. Ann Intern Med. 1997;126:963-972.
78. Pang L, Limsomwong N, Singharaj P. Prophylactic treatment of vivax and falciparum malaria with lowdose doxycycline. J Infect Dis. 1988;158:1124-1127.
79. Pang LW, Limsomwong N, Boudreau EF, Singharaj P. Doxycycline prophylaxis for falciparum malaria. Lancet. 1987;1:1161-1164.
80. Rieckmann KH, Yeo AE, Davis DR, Hutton DC, Wheatley PF, Simpson R. Recent military experience with malaria chemoprophylaxis. Med J Aust. 1993;158: 446-449.
81. Sanchez JL, DeFraites RF, Sharp TW, Hanson RK. Mefloquine or doxycycline prophylaxis in US troops in Somalia. Lancet. 1993;341:1021-1022.
82. Shamiss A, Atar E, Zohar L, Cain Y. Mefloquine versus doxycycline for malaria prophylaxis in intermittent exposure of Israeli Air Force aircrew in Rwanda. Aviat Space Environ Med. 1996;67:872-873.
83. Shanks GD, Barnett A, Edstein MD, Rieckmann KH. Effectiveness of doxycycline combined with primaquine for malaria prophylaxis. Med J Aust. 1995;162:306-307, 309-310.
84. Shanks GD, Roessler P, Edstein MD, Rieckmann KH. Doxycycline for malaria prophylaxis in Australian soldiers deployed to United Nations missions in Somalia and Cambodia. Mil Med. 1995;160:443-445.
85. Taylor WR, Richie TL, Fryauff DJ, et al. Malaria prophylaxis using azithromycin: a double-blind, placebo-controlled trial in Irian Jaya, Indonesia. Clin Infect Dis. 1999;28:74-81.
86. Adehossi E, Parola P, Foucault C, et al. Three-day quinine-clindamycin treatment of uncomplicated falciparum malaria imported from the tropics. Antimicrob Agents Chemother. 2003;47:1173.
87. Ramharter M, Oyakhirome S, Klouwenberg PK, et al. Artesunate-clindamycin versus quinine-clindamycin in the treatment of Plasmodium falciparum malaria: a randomized controlled trial. Clin Infect Dis. 2005;40:1777-1784.
88. Duarte EC, Fontes CJ, Gyorkos TW, Abrahamowicz M. Randomized controlled trial of artesunate plus tetracycline versus standard treatment (quinine plus tetracycline) for uncomplicated Plasmodium falciparum malaria in Brazil. Am J Trop Med Hyg. 1996;54:197-202.
89. Silamut K, Molunto P, Ho M, Davis TM, White NJ. Alpha 1-acid glycoprotein (orosomucoid) and plasma protein binding of quinine in falciparum malaria. Br J Clin Pharmacol. 1991;32:311-315.
90. Winstanley P, Newton C, Watkins W, et al. Towards optimal regimens of parenteral quinine for young African children with cerebral malaria: the importance of unbound quinine concentration. Trans R Soc Trop Med Hyg. 1993;87:201-206.
91. White NJ. The treatment of malaria. N Engl J Med. 1996;335:800-806.
92. Di Perri G, Allegranzi B, Bonora S. Quinine-induced blindness reversed by an increase in alpha1-acid glycoprotein level. Ann Intern Med. 2002;136:339.
93. Severe falciparum malaria: World Health Organization, Communicable Diseases Cluster. Trans R Soc Trop Med Hyg. 2000;94(suppl 1):S1-S90.
94. Anabwani G, Canfield CJ, Hutchinson DB. Combination atovaquone and proguanil hydrochloride vs. halofantrine for treatment of acute Plasmodium falciparum malaria in children. Pediatr Infect Dis J. 1999;18:456-461.
95. Blanchard TJ, Mabey DC, Hunt-Cooke A, et al. Multiresistant falciparum malaria cured using atovaquone and proguanil. Trans R Soc Trop Med Hyg. 1994;88:693.
96. Bouchaud O, Monlun E, Muanza K, et al. Atovaquone plus proguanil versus halofantrine for the treatment of imported acute uncomplicated Plasmodium falciparum malaria in non-immune adults: a randomized comparative trial. Am J Trop Med Hyg. 2000;63:274-279.
97. Bustos DG, Canfield CJ, Canete-Miguel E, Hutchinson DB. Atovaquone-proguanil compared with chloroquine and chloroquine-sulfadoxine- pyrimethamine for treatment of acute Plasmodium falciparum malaria in the Philippines. J Infect Dis. 1999;179:1587-1590.
98. Giao PT, De Vries PJ, Hung LQ, Binh TQ, Nam NV, Kager PA. Atovaquone-proguanil for recrudescent Plasmodium falciparum in Vietnam. Ann Trop Med Parasitol. 2003;97:575-580.
99. Lacy MD, Maguire JD, Barcus MJ, et al. Atovaquone/proguanil therapy for Plasmodium falciparum and Plasmodium vivax malaria in Indonesians who lack clinical immunity. Clin Infect Dis. 2002;35:e92-e95.
100. Llanos-Cuentas A, Campos P, Clendenes M, Canfield CJ, Hutchinson DB. Atovaquone and proguani hydrochloride compared with chloroquine or pyrimethamine/sulfodaxine for treatment of acute Plasmodium falciparum malaria in Peru. Braz J Infect Dis. 2001;5:67-72.
101. Looareesuwan S, Viravan C, Webster HK, Kyle DE, Hutchinson DB, Canfield CJ. Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. Am J Trop Med Hyg. 1996;54:62-66.
102. Looareesuwan S, Wilairatana P, Chalermarut K, Rattanapong Y, Canfield CJ, Hutchinson DB. Efficacy and safety of atovaquone/proguanil compared with mefloquine for treatment of acute Plasmodium falciparum malaria in Thailand. Am J Trop Med Hyg. 1999;60:526-532.
103. Malvy D, Djossou F, Vatan R, et al. Experience with the combination atovaquone-proguanil in the treatment of uncomplicated Plasmodium falciparum malaria - report of 112 cases [article in French]. Med Trop (Mars). 2002;62:229-231.
104. Mulenga M, Sukwa TY, Canfield CJ, Hutchinson DB. Atovaquone and proguanil versus pyrimethamine/sulfadoxine for the treatment of acute falciparum malaria in Zambia. Clin Ther. 1999;21:841-852.
105. Radloff PD, Philipps J, Nkeyi M, Hutchinson D, Kremsner PG. Atovaquone and proguanil for Plasmodium falciparum malaria. Lancet. 1996;347:1511-1514.
106. Sabchareon A, Attanath P, Phanuaksook P, et al. Efficacy and pharmacokinetics of atovaquone and proguanil in children with multidrug-resistant Plasmodium falciparum malaria. Trans R Soc Trop Med Hyg. 1998;92:201-206.
107. Thybo S, Gjorup I, Ronn AM, Meyrowitsch D, Bygberg IC. Atovaquone-proguanil (malarone): an effective treatment for uncomplicated Plasmodium falciparum malaria in travelers from Denmark. J Travel Med. 2004;11:220-223.
108. Uchiyama H, Okamoto A, Sato K, et al. Quinine-resistant severe falciparum malaria effectively treated with atovaquone and proguanil hydrochloride combination therapy. Intern Med. 2004;43:624-627.
109. van Vugt M, Leonardi E, Phaipun L, et al. Treatment of uncomplicated multidrug-resistant falciparum malaria with artesunate-atovaquone-proguanil. Clin Infect Dis. 2002;35:1498-1504.
110. David KP, Alifrangis M, Salanti A, Vestergaard LS, Ronn A, Bygbjerg IB. Atovaquone/proguanil resistance in Africa: a case report. Scand J Infect Dis. 2003;35:897-898.
111. Farnert A, Lindberg J, Gil P, et al. Evidence of Plasmodium falciparum malaria resistant to atovaquone and proguanil hydrochloride: case reports. BMJ. 2003;326:628-629.
112. Fivelman QL, Butcher GA, Adagu IS, Warhurst DC, Pasvol G. Malarone treatment failure and in vitro confirmation of resistance of Plasmodium falciparum isolate from Lagos, Nigeria. Malar J. 2002;1:1.
113. Schwartz E, Bujanover S, Kain KC. Genetic confirmation of atovaquone-proguanil-resistant Plasmodium falciparum malaria acquired by a nonimmune traveler to East Africa. Clin Infect Dis. 2003;37:450-451.
114. Wichmann O, Muehlen M, Gruss H, Mockenhaupt FP, Suttorp N, Jelinek T. Malarone treatment failure not associated with previously described mutations in the cytochrome b gene. Malar J. 2004;3:14.
115. Kuhn S, Gill MJ, Kain KC. Emergence of atovaquone-proguanil resistance during treatment of Plasmodium falciparum malaria acquired by a nonimmune north American traveller to west Africa. Am J Trop Med Hyg. 2005;72:407-409.
116. Schwobel B, Alifrangis M, Salanti A, Jelinek T. Different mutation patterns of atovaquone resistance to Plasmodium falciparum in vitro and in vivo: rapid detection of codon 268 polymorphisms in the cytochrome b as potential in vivo resistance marker. Malar J. 2003;2:5.
117. Boggild AK, Parise ME, et al. Atovaquone-proguanil: report from a CDC expert meeting on malaria chemoprophylaxis (II). Am J Trop Med Hyg. 2007:208-223 76.
118. Health Information for International Travel 2007-2008. Atlanta, Ga: Elsevier; 2007.
119. Product information: Larium brand of mefloquine hydrochloride tablets. Bas, Switzerland: Hoffman-La Roche; 2002.
120. Hall AP, Doberstyn EB, Karnchanachetanee C, et al. Sequential treatment with quinine and mefloquine or quinine and pyrimethamine-sulfadoxine for falciparum malaria. Br Med J. 1977;1:1626-1628.
121. Baird JK, Sustriayu Nalim MF, Basri H, et al. Survey of resistance to chloroquine by Plasmodium vivax in Indonesia. Trans R Soc Trop Med Hyg. 1996;90:409-411.
122. Baird JK, Wiady I, Fryauff DJ, et al. In vivo resistance to chloroquine by Plasmodium vivax and Plasmodium falciparum at Nabire, Irian Jaya, Indonesia. Am J Trop Med Hyg. 1997;56:627-631.
123. Fryauff DJ, Tuti S, Mardi A, et al. Chloroquine-resistant Plasmodium vivax in transmigration settlements of West Kalimantan, Indonesia. Am J Trop Med Hyg. 1998;59:513-518.
124. Murphy GS, Basri H, Purnomo HB, et al. Vivax malaria resistant to treatment and prophylaxis with chloroquine. Lancet. 1993;341:96-100.
125. Rieckmann KH, Davis DR, Hutton DC. Plasmodium vivax resistance to chloroquine? Lancet. 1989;2:1183-1184.
126. Schuurkamp GJ, Spicer PE, Kereu RK, Bulungol PK, Rieckmann KH. Chloroquine-resistant Plasmodium vivax in Papua New Guinea. Trans R Soc Trop Med Hyg. 1992;86:121-122.
127. Sumawinata IW, Subianto B, Leksana B, et al. Very high risk of therapeutic failure with chloroquine for uncomplicated Plasmodium falciparum and P. vivax malaria in Indonesian Papua. Am J Trop Med Hyg. 2003;68:416-420.
128. Whitby M, Wood G, Veenendaal JR, Rieckmann K. Chloroquine-resistant Plasmodium vivax. Lancet. 1989;2:1395.
129. Alcantara AK, Uylangco CV, Sangalang RP, Cross JH. A comparative clinical study of mefloquine and chloroquine in the treatment of vivax malaria. Southeast Asian J Trop Med Public Health. 1985;16:534-538.
130. Collignon P. Chloroquine resistance in Plasmodium vivax. J Infect Dis. 1991;164:222-223.
131. Dixon KE, Pitaktong U, Phintuyothin P. A clinical trial of mefloquine in the treatment of Plasmodium vivax malaria. Am J Trop Med Hyg. 1985;34:435-437.
132. Hanna J. Chloroquine-resistant Plasmodium vivax: how common? Med J Aust. 1993;158:502-503.
133. Harinasuta T, Bunnag D, Lasserre R, Leimer R, Vinijanont S. Trials of mefloquine in vivax and of mefloquine plus "fansidar" in falciparum malaria. Lancet. 1985;1:885-888.
134. Pukrittayakamee S, Chantra A, Simpson JA, et al. Therapeutic responses to different antimalarial drugs in vivax malaria. Antimicrob Agents Chemother. 2000;44:1680-1685.
135. Schwartz IK, Lackritz EM, Patchen LC. Chloroquine-resistant Plasmodium vivax from Indonesia. N Engl J Med. 1991;324:927.
136. Maguire JD, Krisin, Marwoto H, Richie TL, Fryauff DJ, Baird JK. Mefloquine is highly efficacious against chloroquine-resistant Plasmodium vivax malaria and Plasmodium falciparum malaria in Papua, Indonesia. Clin Infect Dis. 2006;42:1067-1072.
137. Looareesuwan S, Wilairatana P, Glanarongran R, et al. Atovaquone and proguanil hydrochloride followed by primaquine for treatment of Plasmodium vivax malaria in Thailand. Trans R Soc Trop Med Hyg. 1999;93:637-640.
138. Baird JK, Basri H, Subianto B, et al. Treatment of chloroquine-resistant Plasmodium vivax with chloroquine and primaquine or halofantrine. J Infect Dis. 1995;171:1678-1682.
139. Glucose-6-phosphate dehydrogenase deficiency. Bull World Health Organ. 1989;67:601-611.
140. Hill DR, Baird JK, Parise ME, Lewis LS, Ryan ET, Magill AJ. Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I. Am J Trop Med Hyg. 2006;75:402-415.
141. Povinelli L, Monson TA, Fox BC, Parise ME, Morrisey JM, Vaidya AB. Plasmodium vivax malaria in spite of atovaquone/proguanil (malarone) prophylaxis. J Travel Med. 2003;10:353-355.
142. Jimenez BC, Navarro M, Huerga H, Lopez-Roman E, Mendoza A, Lopez-Velez R. Tertian malaria (Plasmodium vivax and Plasmodium ovale) in two travelers despite atovaquone-proguanil prophylaxis. J Travel Med. 2006;13:373-375.
143. Alving AS, Johnson CF, Tarlov AR, Brewer GJ, Kellermeyer RW, Carson PE. Mitigation of the haemolytic effect of primaquine and enhancement of its action against exoerythrocytic forms of the Chesson strain of Plasmodium vivax by intermittent regimens of drug administration: a preliminary report. Bull World Health Organ. 1960;22:621-631.
144. Myat-Phone K, Myint O, Myint L, Thaw Z, Kyin Hla A, Nwe Nwe Y. Emergence of chloroquine-resistant Plasmodium vivax in Myanmar (Burma). Trans R Soc Trop Med Hyg. 1993;87:687.
145. Miller KD, Greenberg AE, Campbell CC. Treatment of severe malaria in the United States with a continuous infusion of quinidine gluconate and exchange transfusion. N Engl J Med. 1989;321:65-70.
146. Phillips RE, Warrell DA, White NJ, Looareesuwan S, Karbwang J. Intravenous quinidine for the treatment of severe falciparum malaria: clinical and pharmacokinetic studies. N Engl J Med. 1985;312:1273-1278.
147. van Hensbroek MB, Onyiorah E, Jaffar S, et al. A trial of artemether or quinine in children with cerebral malaria. N Engl J Med. 1996;335:69-75.
148. Newton PN, Angus BJ, Chierakul W, et al. Randomized comparison of artesunate and quinine in the treatment of severe falciparum malaria. Clin Infect Dis. 2003;37:7-16.
149. Molyneux ME, Taylor TE, Thomas CG, Mansor S, Wirima JJ. Efficacy of quinine for falciparum malaria according to previous chloroquine exposure. Lancet. 1991;337:1379-1380.
150. Zucker JR, Campbell CC. Malaria: principles of prevention and treatment. Infect Dis Clin North Am. 1993;7:547-567.
151. White NJ, Looareesuwan S, Warrell DA, Chongsuphajaisiddhi T, Bunnag D, Harinasuta T. Quinidine in falciparum malaria. Lancet. 1981;2:1069-1071.
152. Availability and use of parenteral quinidine gluconate for severe or complicated malaria. MMWR Morb Mortal Wkly Rep. 2000;49:1138-1140.
153. Humar A, Sharma S, Zoutman D, Kain KC. Fatal falciparum malaria in Canadian travellers. CMAJ. 1997;156:1165-1167.
154. Rosenthal PJ, Peterson C, Geertsma FR, Kohl S. Availability of intravenous quinidine for falciparum malaria. N Engl J Med. 1996;335:138.
155. Murphy S, English M, Waruiru C, et al. An open randomized trial of artemether versus quinine in the treatment of cerebral malaria in African children. Trans R Soc Trop Med Hyg. 1996;90:298-301.
156. Warrell DA, Looareesuwan S, Warrell MJ, et al. Dexamethasone proves deleterious in cerebral malaria: a double-blind trial in 100 comatose patients. N Engl J Med. 1982;306:313-319.
157. White NJ, Warrell DA. Managing cerebral malaria. Br Med J (Clin Res Ed). 1982;285:439-440.
158. Dondorp A, Nosten F, Stepniewska K, Day N, White N. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet. 2005;366:717-725.
159. Hoontrakoon S, Suputtamongkol Y. Exchange transfusion as an adjunct to the treatment of severe falciparum malaria. Trop Med Int Health. 1998;3:156-161.
160. Looareesuwan S, Phillips RE, Karbwang J, White NJ, Flegg PJ, Warrell DA. Plasmodium falciparum hyperparasitaemia: use of exchange transfusion in seven patients and a review of the literature. Q J Med. 1990;75:471-481.
161. Burchard GD, Kroger J, Knobloch J, et al. Exchange blood transfusion in severe falciparum malaria: retrospective evaluation of 61 patients treated with, compared to 63 patients treated without, exchange transfusion. Trop Med Int Health. 1997;2:733-740.
162. Powell VI, Grima K. Exchange transfusion for malaria and Babesia infection. Transfus Med Rev. 2002;16:239-250.
163. Pasvol G, Jacobs M. What is the future of exchange transfusion for falciparum malaria? J Infect. 1999;39:183-184.
164. Riddle MS, Jackson JL, Sanders JW, Blazes DL. Exchange transfusion as an adjunct therapy in severe Plasmodium falciparum malaria: a meta-analysis. Clin Infect Dis. 2002;34:1192-1198.
165. Crawley J, Waruiru C, Mithwani S, et al. Effect of phenobarbital on seizure frequency and mortality in childhood cerebral malaria: a randomised, controlled intervention study. Lancet. 2000;355:701-706.
166. Kochar D, Kumawat B, Bajiya HN, Chauhan S, Kochar SK, Agarwal RP. Prophylactic role of single dose phenobarbitone in preventing convulsions in cerebral malaria. J Assoc Physicians India. 1997;45:123-124.
167. White NJ, Looareesuwan S, Phillips RE, Chanthavanich P, Warrell DA. Single dose phenobarbitone prevents convulsions in cerebral malaria. Lancet. 1988;2:64-66.
168. Hoffman SL, Rustama D, Punjabi NH, et al. High-dose dexamethasone in quinine-treated patients with cerebral malaria: a double-blind, placebo-controlled trial. J Infect Dis. 1988;158:325-331.
169. Prasad K, Garner P. Steroids for treating cerebral malaria. Cochrane Database Syst Rev. 2000;(2):CD000972.
170. Borochovitz D, Crosley AL, Metz J. Disseminated intravascular coagulation with fatal haemorrhage in cerebral malaria. Br Med J. 1970;2:710.
171. Hemmer CJ. Neither heparin nor acetylsalicylic acid influence the clinical course in human Plasmodium falciparum malaria: a prospective randomized study. Am J Trop Med Hyg. 1991;45:608-612.
172. Munir M, Tjandra H, Rampengan TH, Mustadjab I, Wulur FH. Heparin in the treatment of cerebral malaria. Paediatr Indones. 1980;20:47-50.
173. Punyagupta S, Srichaikul T, Akarawong K. The use of heparin in fatal pulmonary edema due to acute falciparum malaria. J Med Assoc Thai. 1972;55:121-131.
174. Punyagupta S, Srichaikul T, Nitiyanant P, Petchclai B. Acute pulmonary insufficiency in falciparum malaria: summary of 12 cases with evidence of disseminated intravascular coagulation. Am J Trop Med Hyg. 1974;23:551-559.
175. Rampengan TH. Cerebral malaria in children: comparative study between heparin, dexamethasone and placebo. Paediatr Indones. 1991;31:59-66.
176. Reid HA. Letter: Adjuvant treatment of severe falciparum malaria, intravascular coagulation, and heparin. Lancet. 1975;1:167-168.
177. Thuma PE, Mabeza GF, Biemba G, et al. Effect of iron chelation therapy on mortality in Zambian children with cerebral malaria. Trans R Soc Trop Med Hyg. 1998;92:214-218.
178. Thuma PE, Olivieri NF, Mabeza GF, et al. Assessment of the effect of the oral iron chelator deferiprone on asymptomatic Plasmodium falciparum parasitemia in humans. Am J Trop Med Hyg. 1998;58:358-364.
179. Looareesuwan S, Wilairatana P, Vannaphan S, et al. Pentoxifylline as an ancillary treatment for severe falciparum malaria in Thailand. Am J Trop Med Hyg. 1998;58:348-353.
180. Agbenyega T, Planche T, Bedu-Addo G, et al. Population kinetics, efficacy, and safety of dichloro-acetate for lactic acidosis due to severe malaria in children. J Clin Pharmacol. 2003;43:386-396.
181. Parise M, Lewis LS. Severe malaria: North American perspective. In: Feldman CSG, ed. Tropical and Parasitic Infections in the ICU. New York, NY: Springer Science-Business Media Inc; 2005:17-37.
182. Phillips RE, Looareesuwan S, White NJ, et al. Hypoglycaemia and antimalarial drugs: quinidine and release of insulin. Br Med J (Clin Res Ed). 1986;292:1319-1321.
183. White NJ, Warrell DA, Chanthavanich P, et al. Severe hypoglycemia and hyperinsulinemia in falciparum malaria. N Engl J Med. 1983;309:61-66.
184. White N. Controversies in the management of severe falciparum malaria. In: Pasvol G, ed. Balliere's Clinical Infectious Diseases: Malaria [Volume 2]. London, England: Baillière Tindall; 1995:309-330.
185. Butler T, Tong MJ, Fletcher JR, Dostalek RJ, Robbins TO. Blood coagulation studies in Plasmodium falciparum malaria. Am J Med Sci. 1973;265:63-67.
186. Phillips RE, Looareesuwan S, Warrell DA, et al. The importance of anaemia in cerebral and uncomplicated falciparum malaria: role of complications, dyserythropoiesis and iron sequestration. Q J Med. 1986;58:305-323.
187. Marino P. The ICU Book. 2nd ed. Baltimore, Md: Williams & Wilkins; 1998.
188. Davis TM, Pukrittayakamee S, Woodhead JS, Holloway P, Chaivisuth B, White NJ. Calcium and phosphate metabolism in acute falciparum malaria. Clin Sci (Lond). 1991;81:297-304.
189. Newton CR, Hien TT, White N. Cerebral malaria. J Neurol Neurosurg Psychiatry. 2000;69:433-441.
190. U.D.E. Group, ed. USP DI Drug Information for the Healthcare Provider. 23rd ed. Taunton, Mass: Micromedex Inc; 2003.
191. Conchie JM, Munroe JD, Anderson DO. The incidence of staining of permanent teeth by the tetracyclines. Can Med Assoc J. 1970;203:351-356.
192. Dubos F, Delattre P, Demar M, Carme B, Gendrel D. Safety of mefloquine in infants with acute falciparum malaria. Pediatr Infect Dis J. 2004;23:679-681.
193. Luxemburger C, Price RN, Nosten F, Ter Kuile FO, Chongsuphajaisiddhi T, White NJ. Mefloquine in infants and young children. Ann Trop Paediatr. 1996;16:281-286.
194. Sowunmi A, Oduola AM. Open comparison of mefloquine, mefloquine/ sulfadoxine/pyrimethamine and chloroquine in acute uncomplicated falciparum malaria in children. Trans R Soc Trop Med Hyg. 1995;89:303-305.
195. ter Kuile FO, Nosten F, Luxemburger C, et al. Mefloquine treatment of acute falciparum malaria: a prospective study of non-serious adverse effects in 3673 patients. Bull World Health Organ. 1995;73:631-642.
196. ter Kuile FO, Nosten F, Thieren M, et al. High-dose mefloquine in the treatment of multidrug-resistant falciparum malaria. J Infect Dis. 1992;166:1393-1400.
197. Canadian recommendations for the prevention and treatment of malaria among international travellers. Committee to Advise on Tropical Medicine and Travel CATMAT), Laboratory for Disease Control. Can Commun Dis Rep. 2000;26(suppl 2):i-vi, 1-42.
198. Looareesuwan S, Phillips RE, White NJ, et al. Quinine and severe falciparum malaria in late pregnancy. Lancet. 1985;2:4-8.
199. McGready R, Keo NK, Villegas L, White NJ, Looareesuwan S, Nosten F. Artesunate-atovaquone-proguanil rescue treatment of multidrug-resistant Plasmodium falciparum malaria in pregnancy: a preliminary report. Trans R Soc Trop Med Hyg. 2003;97:592-594.
200. McGready R, Stepniewska K, Edstein MD, et al. The pharmacokinetics of atovaquone and proguanil in pregnant women with acute falciparum malaria. Eur J Clin Pharmacol. 2003;59:545-552.
201. Nosten F, Vincenti M, Simpson J, et al. The effects of mefloquine treatment in pregnancy. Clin Infect Dis. 1999;28:808-815.
202. Nosten F, Karbwang J, White NJ, et al. Mefloquine antimalarial prophylaxis in pregnancy: dose finding and pharmacokinetic study. Br J Clin Pharmacol. 1990;30:79-85.
203. Nosten F, ter Kuile F, Maelankiri L, et al. Mefloquine prophylaxis prevents malaria during pregnancy: a double-blind, placebo-controlled study. J Infect Dis. 1994;169:595-603.
204. Phillips-Howard PA, Steffen R, Kerr L, et al. Safety of mefloquine and other antimalarial agents in the first trimester of pregnancy. J Travel Med. 1998;5:121-126.
205. Steketee RW, Wirima JJ, Slutsker L, Khoromana CO, Heymann DL, Breman JG. Malaria treatment and prevention in pregnancy: indications for use and adverse events associated with use of chloroquine or mefloquine. Am J Trop Med Hyg. 1996;55(suppl):50-56.
206. Vanhauwere B, Maradit H, Kerr L. Post-marketing surveillance of prophylactic mefloquine (Lariam) use in pregnancy. Am J Trop Med Hyg. 1998;58:17-21.
207. Lackritz EM, Lobel HO, Howell BJ, Bloland P, Campbell CC. Imported Plasmodium falciparum malaria in American travelers to Africa: implications for prevention strategies. JAMA. 1991;265:383-385.
208. Lobel HO, Campbell CC, Schwartz IK, Roberts JM. Recent trends in the importation of malaria caused by Plasmodium falciparum into the United States from Africa. J Infect Dis. 1985;152:613-617.
209. Nahlen BL, Lobel HO, Cannon SE, Campbell CC. Reassessment of blood donor selection criteria for United States travelers to malarious areas. Transfusion. 1991;31:798-804.